A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Intravenous FDY-5301 in Tourniquet Induced Sarcopenia in knee-replacement patients
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2019
Price : $35 *
At a glance
- Drugs FDY 5301 (Primary)
- Indications Reperfusion injury
- Focus Therapeutic Use
- Sponsors Faraday Pharmaceuticals
- 15 Aug 2019 Planned End Date changed from 14 Feb 2019 to 30 Aug 2019.
- 15 Aug 2019 Status changed from not yet recruiting to recruiting.
- 26 Jun 2018 New trial record